The UK’s Imperial College London has reported that early data from the REMAP-CAP trial showed Roche’s arthritis drug, Actemra (tocilizumab), is expected to reduce deaths and time spent in intensive care in critically ill patients with severe Covid-19.

An anti-inflammation drug, Actemra reached a key efficacy endpoint for Covid-19 patients.

The trial is sponsored by the UMC Utrecht in Europe and is led by Imperial College London and ICNARC in the UK.

The analysis included results from 303 patients who randomly received Actemra, sarilumab, anakinra, interferon, or no immune modulator.

Patients who received Actemra were more likely to improve as compared to patients who did not receive any immune modulator, data showed.

Improvement was analysed based on a combination of the requirements for organ support including a ventilator, ICU and surviving the hospital admission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was noted that tocilizumab was 99.75% superior to no immune modulation.

Imperial College London anaesthesia and critical care chair Anthony Gordon said: “These early findings show that a single course of treatment with this immune-modulating drug can significantly improve the outcomes for the most critically ill Covid-19 patients in intensive care.

“Once we have completed the analysis of the full dataset, we hope these findings will allow critical care teams around the world to improve the outcomes of the sickest Covid-19 patients.”

Detailed data from the trial will be published in a couple of weeks.

Separately, the REMAP-CAP trial found that AbbVie’s AIDS drug cocktail lopinavir/ritonavir was ineffective and provided no additional benefit to critically ill Covid-19 patients.

In September, Roche had reported that Actemra reduced the need for ventilators in hospitalised patients with the disease.

The drug has also failed in a separate trial on hospitalised patients with severe Covid-19 related pneumonia.